Effects of medroxyprogesterone acetate and beta-estradiol on interleukin-6 production from osteoblasts and bone marrow macrophages of Wistar rats of different ages.
Using 18-week-old and 52-week-old Wistar rats, we examined interleukin-6 (IL-6) production from osteoblasts and bone marrow macrophages treated with medroxyprogesterone acetate (MPA) and/or beta-estradiol. The level of IL-6 production by osteoblasts was increased by treatment with MPA and, reversely, decreased by treatment with beta-estradiol. These changes were especially remarkable in osteoblasts of 52-week-old rats. Additionally, and in contrast, the production of IL-6 by bone marrow macrophages was not significantly changed by treatment with both agents. These data suggest that because the increased production of IL-6 by osteoblasts treated with MPA in opposition with beta-estradiol, MPA should be careful for osteoporosis dependent upon osteoclasts activated by IL-6. Finally, there was a marked difference in the amount of IL-6 produced between osteoblasts and bone marrow macrophages.
D000375:Aging / Q000378:metabolism*; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects* / Q000378:metabolism; D001854:Bone Marrow Cells; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D015850:Interleukin-6 / Q000096:biosynthesis*; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology*; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D015850:Interleukin-6; D004958:Estradiol; D017258:Medroxyprogesterone Acetate